GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - EDITAS MEDICINE INC

Financial Performance:

• Raised $125 million in financing earlier in the year.
• Cash runway extended to the second half of 2028.
• Funding is allocated to complete Part 1 (dose escalation) and progress through most of Part 2 (expansion) of the Phase 1-2 trial for EDIT-401.
• No revenue or product sales reported as the company is pre-revenue clinical stage.

Guidance and Future Outlook:

• Aims to begin dosing patients in the EDIT-401 Phase 1-2 trial within the current year.
• Plans to announce safety and tolerability data from the first cohort in Q1 of the upcoming year.
• Targets top-line data from subsequent cohorts, including LDL cholesterol reduction and efficacy, for the second half of 2027.
• Long-term goal is to pursue registration studies in a target population potentially exceeding HEFH, including the ~10 million US patients with established cardiovascular disease and high risk.
• Ambition to achieve LDL-C reductions greater than 60%, ideally replicating the 90% reduction observed in non-human primate models.

Business Segments and Product Lines:

• Strategy: Transitioned to an entirely focused in vivo CRISPR editing company.
• Lead Asset (EDIT-401): A novel in vivo CRISPR therapy designed to upregulate the LDL receptor (LDLR) gene by editing the 3' UTR of the LDLR gene, mimicking a naturally occurring human genetic variant.
• Mechanism: Directly increases LDLR synthesis rather than inhibiting degradation (unlike PCSK9 inhibitors).
• Delivery: Utilizes a lipid nanoparticle (LNP) system dressed with GalNAc to ensure efficient hepatocyte entry, overcoming uptake issues associated with LDLR loss-of-function mutations.
• Study Design: Phase 1-2 HORIZON study following a 3+3 dose escalation design with at least three cohorts of three patients each.

Market and Competitive Landscape:

• Market Size: Addresses the ~30% of cardiovascular disease patients who cannot reach LDL-C targets with standard of care, plus a total addressable market of ~10 million US patients with high-risk cardiovascular disease.
• Differentiation: Claims superior efficacy in preclinical models (90% LDL-C reduction) compared to existing PCSK9 inhibitors which target receptor recycling/degradation.
• Competitive Landscape: References Verve Therapeutics (using GalNAc-LNP) as a peer demonstrating the viability of the delivery approach; notes upcoming precedents from other in vivo editors and recent approvals like Inclisiran (Lipoprotein Lp(a) data context) and PCSK9 inhibitors.
• Regulatory Path: Anticipates using LDL-C as a surrogate endpoint for approval, citing it as the "final common pathway" for LDL reduction, similar to approvals for other lipid-lowering therapies.

Risks and Challenges:

• Safety Concerns: Potential theoretical risks include LDL levels being "too low" (mitigated by data on Icelandic kindreds and PCSK9 knockouts showing safe single-digit LDL) and endoplasmic reticulum stress (mitigated by the low abundance of LDLR protein).
• Diabetes Risk: Addresses concerns regarding new-onset diabetes associated with extremely low LDL levels; management notes meta-analyses suggest this risk is likely at background levels.
• Regulatory Uncertainty: FDA requirements for safety databases in gene editing remain to be fully defined; expects precedents to be clearer as other programs (e.g., Verve/Lilly) progress.
• Heterogeneity: Concerns regarding variable patient response to LNP delivery are mitigated by GalNAc conjugation, which reduces variance.

Management Commentary and Tone:

• Tone: Highly confident and ambitious; management emphasizes the transformative potential of their specific editing approach.
• Narrative: Frames the company as having "completed the evolution" into a pure in vivo CRISPR entity with a validated biological strategy.
• Physician Sentiment: Describes physician enthusiasm driven by the potential to treat patients who fail all standard care, rather than just incremental improvements.
• Commercial Viability: States the current capitalization is sufficient to service the HEFH market and potentially the broader high-risk population without immediate need for partnership.

Analyst Questions and Answers:

• Q: Mechanism depth vs. PCSK9 inhibitors. A: EDIT-401 upregulates synthesis; PCSK9 inhibitors inhibit degradation/recycling, explaining the deeper knockdown potential.
• Q: Patient selection criteria. A: Focus on High-Risk patients (HEFH) who fail standard care; high-risk ASCVD patients with established events are a secondary target.
• Q: Dose escalation and timing. A: Starts with non-therapeutic doses for safety; expects safety data in Q1 and efficacy data (LDL reduction) in H2 2027.
• Q: Market reach beyond HEFH. A: Plans to expand to the 10 million US patients with established CVD and high risk.
• Q: Regulatory pathway. A: Confident in LDL-C surrogate approval given its status as the final common pathway, similar to recent approvals.
• Q: Safety of extreme LDL reduction. A: References data from Icelandic kindreds (13 mg/dL) and long-term studies showing single-digit LDL is safe.

Other Key Points:

• Off-Target Analysis: Extensive in silico, in vitro, and biochemical testing has been conducted, revealing a clean off-target profile using tools developed internally by Editas.
• Non-Human Primate Data: Durability of the 90% LDL reduction effect has been observed for up to 10 months.
• Delivery Tech: GalNAc conjugation is critical for bypassing the impaired LDLR uptake pathway in HEFH patients, ensuring efficacy in both wild-type and heterozygous loss-of-function models.
• Future Capital: The recent $125M raise removes immediate financial constraints regarding the Phase 1-2 trial execution.